• Home
• About Lipoxen
• Our Technologies
• Pipeline
• Partnering
• Corporate Governance
• Investor Centre
• News
  • FAQ
  • Contact us
  • Careers

Senior Management Appointment

30 September 2009

Lipoxen plc (AIM: LPX), a bio-pharmaceutical company specialising in the development of high-value differentiated biologicals, vaccines and siRNA delivery, is pleased to announce the appointment of Dr David Moss as Director of Project Management. Dr Moss's appointment builds on Lipoxen's announcement today that it has been appointed the lead member of the grant consortium for its controlled-release nanoparticle vaccine programme by the Technology Strategy Board, the Government organisation charged with driving UK innovation.

Dr Moss joined the Company in early September and is charged not only with advancing the Technology Strategy Board programme in particular (given his substantial experience and track record in developing innovative vaccine formulations), but also with both strengthening the Lipoxen management team at the operating level and furthering the Company's Business Development efforts, especially but not exclusively, the initiation of new vaccine and siRNA projects.

Dr Moss has almost thirty years of research, development and project management experience gained from roles in both academia and the private biotech sector. His focus during this period has been on the development of vaccines for veterinary and human applications. He joins Lipoxen from Cambridge Biostability Ltd (CBL) where he was Director of Research and was responsible for the company's entire research programme focused on the development of thermostable vaccines and biopharmaceuticals. This included the Technology Strategy Board-funded vaccine programme. Prior to CBL, he was Project Manager at Intervet UK (now Intervet Schering-Plough), a global veterinary vaccine and research and development company.

Commenting on Dr Moss's appointment, M. Scott Maguire, CEO of Lipoxen, said:

"Dr Moss brings to Lipoxen both substantial commercial experience as well as exceptional vaccine development knowledge including, very pertinently, a deep familiarity with the Technology Strategy Board programme. Lipoxen's influenza vaccine development project is a key element of the Company's preclinical pipeline and it will be driven forward by Dr Moss as part of his overall scope of responsibilities which also includes top level project management of the burgeoning schedule of initiatives being undertaken by the Company. We welcome David Moss to the Lipoxen management team and wish him every possible success in his new role."

Enquiries: